Sarepta Therapeutics (SRPT) Gets a Hold from RBC Capital
RBC Capital analyst Brian Abrahams maintained a Hold rating on Sarepta Therapeutics (SRPT – Research Report) on April 3 and set a price target ...
Stocktwits on MSN20h
Sarepta Therapeutics Temporarily Halts Three Clinical Studies Of Elevidys: Retail Is Dull While Stock Drops
Shares of Sarepta Therapeutics, Inc. (SRPT) traded over 2% lower in afternoon trade on Friday after the company said it has ...
Ousted Vaccine Chief Says RFK Jr.’s Team Sought Data to Justify Anti-Science Stance
Peter Marks says the new health secretary’s team wants to show vaccines aren’t safe while promoting dangerous and unproven ...